Alzheimer's Blood Test Improves Diagnostic Accuracy in Primary Care
A blood test for Alzheimer's disease biomarkers significantly improved diagnostic accuracy among both primary care physicians and specialists in a real-world study.
London – A blood test measuring key Alzheimer's disease biomarkers has demonstrated significant improvements in diagnostic accuracy for physicians, according to new data presented at the Alzheimer's Association International Conference (AAIC) 2026 in London. The findings suggest the test can elevate primary care physicians' diagnostic capabilities to a level comparable with specialists, a critical step toward broader access to accurate diagnoses.
In one of the first real-world studies of its kind, involving over 1,300 patients and 165 physicians, the blood-based biomarker test substantially enhanced the accuracy of Alzheimer's diagnoses in both primary and specialty care settings. The test analyzes levels of amyloid beta and phosphorylated tau, abnormal proteins linked to the disease.
Comparative analysis revealed that primary care physicians achieved diagnostic accuracy of approximately 90% after reviewing blood test results, on par with specialists. This led to diagnosis changes for about one-third of patients and adjustments in future care plans for over half. The study highlighted the test's particular utility in helping primary care physicians rule out Alzheimer's as a cause of cognitive symptoms.
Currently, definitive Alzheimer's diagnosis often relies on expensive and less accessible methods like PET scans or spinal fluid analysis. This blood test offers a pathway to bring high-accuracy diagnostics closer to patients, potentially reducing delays and improving accessibility to timely and precise diagnosis and treatment.